Advertisement

Clinical PET pp 314-324 | Cite as

Hepatobiliary Tumors

  • Byung-Tae Kim
  • E. Edmund Kim
Chapter
  • 252 Downloads

Abstract

Cancers of the liver may arise in the parenchymal cells (hepatocellular cancers), or from the intrahepatic bile ducts (cholangiocarcinomas), or metastasize from other organ tumors.

Keywords

Positron Emission Tomography Primary Sclerosing Cholangitis Intrahepatic Bile Duct Axial Compute Tomography Image Surrounding Liver Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dienstag JL, Isselbacher K. Tumors of the liver and biliary tract. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 1998: 588–591.Google Scholar
  2. 2.
    Fukuda H, Matsuzawa T, Abe Y, et al. Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro2-deoxy-D-mannose: a new tracer for cancer detection. Eur J Nucl Med 1982; 7: 294–297.PubMedGoogle Scholar
  3. 3.
    Yonekura Y, Benua RS, Brill AB, et al. Increased accumulation of 2-deoxy2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133–1137.PubMedGoogle Scholar
  4. 4.
    Paul R, Ahonen A, Roeda D, Nordman E. Imaging of hepatoma with 18Ffluorodeoxyglucose. Lancet 1985; 1 (8419): 50–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Nagata Y, Yamamoto K, Hiraoka M, et al. Monitoring liver tumor therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr 1990; 14: 370–374.PubMedCrossRefGoogle Scholar
  6. 6.
    Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 333–339.PubMedGoogle Scholar
  7. 7.
    Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965–1969.PubMedGoogle Scholar
  8. 8.
    Delbeke D, Martin WH, Martin PS, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133: 510–516.PubMedCrossRefGoogle Scholar
  9. 9.
    Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314–3319.PubMedCrossRefGoogle Scholar
  10. 10.
    Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Arm Nucl Med 2000; 14: 121–126.CrossRefGoogle Scholar
  11. 11.
    Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96: 1877–1880.PubMedCrossRefGoogle Scholar
  12. 12.
    Koyama K, Okamura T, Kawabe J, et al. The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 1999; 16: 169–176.CrossRefGoogle Scholar
  13. 13.
    Morikawa H, Shiomi S, Sasaki N, et al. Hepatocellular carcinoma monitored by F-18 fluorodeoxyglucose positron emission tomography after laparoscopic microwave coagulation therapy. Clin Nucl Med 1999; 24: 536538.Google Scholar
  14. 14.
    Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33: 1029–1035.PubMedCrossRefGoogle Scholar
  15. 15.
    Keiding S, Hansen SB, Rasmussen HH, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28: 700–706.PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta N, Bradfield H. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms. Semin Nucl Med 1996; 26: 65–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Imbriaco M, Akhurst T, Hilton S, et al. Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging 2003; 3: 107–114.CrossRefGoogle Scholar
  18. 18.
    Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171: 21–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Frohlich A, Diederichs CG, Staib L, et al. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999; 40: 250–255.PubMedGoogle Scholar
  20. 20.
    Hayashi N, Tamaki N, Yonekura Y, et al. Imaging of the hepatocellular carcinoma using dynamic positron emission tomography with nitrogen-13 ammonia. J Nucl Med 1995; 26: 254–257.Google Scholar
  21. 21.
    Dimitrakopoulou-Strauss A, Gutzler F, Strauss LG, et al. PET-Studien mit C-11-Athanol bei der intratumoralen therapie von hepatozellularen karzinomen. Radiology 1996; 36: 744–749.CrossRefGoogle Scholar
  22. 22.
    Dimitrakopoulou-Strauss A, Strauss LG, et al. Pharmacokinetic imaging of 11C ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous ethanol injection. Radiology 1999; 211: 681–686.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Byung-Tae Kim
  • E. Edmund Kim

There are no affiliations available

Personalised recommendations